Company

Xencor, Inc.

Xencor develops antibody therapeutics using its XmAb protein engineering platform.

About

Xencor develops antibody therapeutics using its XmAb protein engineering platform, with a focus on oncology and other serious diseases. Founded in 1997, the company is based in Monrovia, US, and is led by CEO Bassil Dahiyat. Its pipeline includes bispecific antibodies and other drug candidates in clinical testing. Xencor raised USD 70.00 mn in its IPO on December 3, 2013.

3Funding rounds

4Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in